[go: up one dir, main page]

CY1115171T1 - Ιατρικο φαρμακο - Google Patents

Ιατρικο φαρμακο

Info

Publication number
CY1115171T1
CY1115171T1 CY20141100316T CY141100316T CY1115171T1 CY 1115171 T1 CY1115171 T1 CY 1115171T1 CY 20141100316 T CY20141100316 T CY 20141100316T CY 141100316 T CY141100316 T CY 141100316T CY 1115171 T1 CY1115171 T1 CY 1115171T1
Authority
CY
Cyprus
Prior art keywords
group
formula
hydrogen atom
atoms
present
Prior art date
Application number
CY20141100316T
Other languages
English (en)
Inventor
Hironori Matsuyama
Kenji Ohnishi
Takashi Nakagawa
Hideki Takasu
Makoto Sakamoto
Kumi Higuchi
Keisuke Miyajima
Satoshi Yamada
Masaaki Motoyama
Yutaka Kojima
Koichi Yasumura
Takeshi Kodama
Shun Otsuji
Keizo Kan
Takumi Sumida
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1115171T1 publication Critical patent/CY1115171T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ένα αντικείμενο της παρούσας εφεύρεσης είναι να παρέχει ιατρικό φάρμακο πολύ βελτιωμένο στη δραστικότητα κατά του όγκου και εξαιρετικής ασφάλειας. Σύμφωνα προς την παρούσα εφεύρεση, παρέχεται ένα ιατρικό φάρμακο που περιέχει μία ένωση που αντιπροσωπεύεται από τον ακόλουθο γενικό τύπο (1) ή άλας αυτής ως δραστικό συστατικό: [Τύπος 1] όπου το Χ1, αντιπροσωπεύει άτομο αζώτου ή μια ομάδα -CH =, το R1 αντιπροσωπεύει μια ομάδα -ZR6, όπου το Ζ αντιπροσωπεύει μία ομάδα -CO-, ομάδα -CH(OH)- ή τις παρόμοιες, το R6 αντιπροσωπεύει 5-μελή έως 15-μελή μονοκυκλική, δικυκλική ή τρικυκλική κορεσμένη ή ακόρεστη ετεροκυκλική ομάδα έχουσα 1 έως 4 άτομα αζώτου, άτομα οξυγόνου ή άτομα θείου, το R2 αντιπροσωπεύει άτομο υδρογόνου ή άτομο αλογόνου, το Υ αντιπροσωπεύει μία ομάδα -Ο-, μία ομάδα -CO-, μία ομάδα -CH(OH)- ή κατώτερη αλκυλένο ομάδα και το Α αντιπροσωπεύει [Τύπος 2] όπου το R3 αντιπροσωπεύει άτομο υδρογόνου, κατώτερη αλκόξυ ομάδα ή τις παρόμοιες, το p αντιπροσωπεύει 1 ή 2, το R4 αντιπροσωπεύει ιμιδαζολύλ κατώτερη αλκύλ ομάδα ή τις παρόμοιες.
CY20141100316T 2005-12-05 2014-05-05 Ιατρικο φαρμακο CY1115171T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005351255 2005-12-05
EP06834365.6A EP1957073B1 (en) 2005-12-05 2006-12-04 Medicinal drug

Publications (1)

Publication Number Publication Date
CY1115171T1 true CY1115171T1 (el) 2016-12-14

Family

ID=38051953

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100316T CY1115171T1 (el) 2005-12-05 2014-05-05 Ιατρικο φαρμακο

Country Status (21)

Country Link
US (1) US8236826B2 (el)
EP (1) EP1957073B1 (el)
KR (1) KR101157004B1 (el)
CN (1) CN101321529B (el)
AR (1) AR056885A1 (el)
AU (1) AU2006323700B2 (el)
BR (1) BRPI0619349A2 (el)
CA (1) CA2630468C (el)
CY (1) CY1115171T1 (el)
DK (1) DK1957073T3 (el)
ES (1) ES2463450T3 (el)
IL (1) IL191544A0 (el)
MY (1) MY146514A (el)
NO (1) NO20081934L (el)
PL (1) PL1957073T3 (el)
PT (1) PT1957073E (el)
RU (1) RU2444362C2 (el)
SI (1) SI1957073T1 (el)
TW (1) TWI332838B (el)
WO (1) WO2007066784A2 (el)
ZA (1) ZA200804445B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100927563B1 (ko) 2004-08-06 2009-11-23 오쓰까 세이야꾸 가부시키가이샤 방향족 화합물
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
JP2012509879A (ja) 2008-11-21 2012-04-26 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー アダマンチルベンズアミド化合物
JP5487202B2 (ja) 2009-04-20 2014-05-07 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
JP5758395B2 (ja) 2009-10-15 2015-08-05 ザ チルドレンズ メディカル センター コーポレイション 疼痛を治療するためのセピアプテリンレダクターゼ阻害薬
PL2528897T3 (pl) * 2010-01-29 2015-03-31 Otsuka Pharma Co Ltd Di-podstawione pochodne pirydyny jako leki przeciwnowotworowe
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
PL2624833T3 (pl) 2010-10-04 2015-05-29 Otsuka Pharma Co Ltd Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
IN2014MN00226A (el) * 2011-07-05 2015-09-25 Lupin Ltd
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
US9376376B2 (en) 2012-03-14 2016-06-28 Sinochem Corporation Substitute diphenylamine compounds use thereof as antitumor agents
JP6066806B2 (ja) * 2012-04-03 2017-01-25 大塚製薬株式会社 医薬
BR122017003181A2 (pt) 2013-02-19 2019-09-10 Ono Pharmaceutical Co composto inibidor de trk, composição farmacêutica e medicamento compreendendo dito composto e seu uso para profilaxia e/ou terapia de doença relacionada à trk e/ou para inibir trk
PE20160434A1 (es) * 2013-09-09 2016-05-25 Peloton Therapeutics Inc Eteres de arilo y sus usos
WO2015179414A1 (en) * 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
TW201617314A (zh) * 2014-09-10 2016-05-16 第一三共股份有限公司 羧酸衍生物
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
WO2020059841A1 (ja) * 2018-09-21 2020-03-26 国立大学法人 長崎大学 プリオン病治療薬
IL314626A (en) * 2022-02-28 2024-09-01 Sironax Ltd Preparation of RIP1 modulators and their uses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629102A (el) * 1961-03-29
NL7111711A (el) 1970-09-17 1972-03-21
US3715375A (en) * 1970-09-17 1973-02-06 Merck & Co Inc New diphenyl sulfones
GB1494117A (en) 1974-11-02 1977-12-07 Bayer Ag Process for the preparation of acid amides
DE2707659A1 (de) * 1977-02-23 1978-08-24 Bayer Ag Selbstvernetzbare polyurethane
DE2707660C2 (de) * 1977-02-23 1985-12-19 Bayer Ag, 5090 Leverkusen Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung
DE2812252A1 (de) * 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
EP0500495A3 (en) * 1991-02-21 1993-04-07 Ciba-Geigy Ag Thermosetting composition
DE69314718T2 (de) * 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
AU7006094A (en) 1993-06-30 1995-01-24 Wellcome Foundation Limited, The Anti-atherosclerotic diaryl compounds
JPH11511121A (ja) 1995-06-07 1999-09-28 インスティテュート オブ マテリア メディカ カルコンレチノイドおよびその使用方法
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
EP1060175B1 (de) 1998-02-06 2004-11-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
EP1060171A2 (de) 1998-02-06 2000-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
EP1101755B1 (en) 1998-07-24 2004-10-06 Teijin Limited Anthranilic acid derivatives
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000046203A2 (en) 1999-02-04 2000-08-10 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6159694A (en) * 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
JP4609691B2 (ja) 1999-07-01 2011-01-12 味の素株式会社 複素環化合物及びその医薬用途
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2001089450A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
AU3408901A (en) * 2000-02-15 2001-08-27 Teijin Ltd Cancer remedy comprising anthranilic acid derivative as active ingredient
IL152830A0 (en) 2000-05-22 2003-06-24 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
WO2002026191A2 (en) 2000-09-28 2002-04-04 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP1211235A3 (en) 2000-11-30 2004-01-02 JFE Chemical Corporation Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof
JP2004269356A (ja) 2000-12-27 2004-09-30 Ajinomoto Co Inc 創傷部癒着防止剤
GB2374009A (en) 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
YU94103A (sh) 2001-06-20 2006-03-03 Pfizer Products Inc. Novi derivati sulfonske kiseline
JP2005504059A (ja) 2001-08-24 2005-02-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 疾患を処置するための置換アリール7−アザ[2.2.1]ビシクロヘプタン
KR20040047941A (ko) 2001-10-22 2004-06-05 화이자 프로덕츠 인크. Ccr1 수용체 길항제 활성을 갖는 피페라진 유도체
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
EP1480977A2 (en) 2002-02-15 2004-12-01 PHARMACIA & UPJOHN COMPANY Substituted aryl compounds for treatment of disease
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
JP2004035475A (ja) 2002-07-03 2004-02-05 Ajinomoto Co Inc TGFβ作用抑制剤
TW201018661A (en) * 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ZA200510137B (en) * 2003-07-24 2007-04-25 Leo Pharma As Novel aminobenzophenone compounds
KR100927563B1 (ko) * 2004-08-06 2009-11-23 오쓰까 세이야꾸 가부시키가이샤 방향족 화합물
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
TWI440638B (zh) * 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物

Also Published As

Publication number Publication date
ZA200804445B (en) 2009-11-25
IL191544A0 (en) 2008-12-29
WO2007066784A2 (en) 2007-06-14
AR056885A1 (es) 2007-10-31
EP1957073A2 (en) 2008-08-20
KR20080070054A (ko) 2008-07-29
RU2008127325A (ru) 2010-01-20
WO2007066784A3 (en) 2007-10-25
CN101321529B (zh) 2012-09-05
CN101321529A (zh) 2008-12-10
MY146514A (en) 2012-08-15
US8236826B2 (en) 2012-08-07
CA2630468C (en) 2015-01-20
EP1957073B1 (en) 2014-04-23
NO20081934L (no) 2008-08-13
HK1123219A1 (en) 2009-06-12
TW200800200A (en) 2008-01-01
RU2444362C2 (ru) 2012-03-10
DK1957073T3 (da) 2014-05-12
PT1957073E (pt) 2014-05-12
SI1957073T1 (sl) 2014-08-29
US20100004438A1 (en) 2010-01-07
ES2463450T3 (es) 2014-05-28
AU2006323700A1 (en) 2007-06-14
BRPI0619349A2 (pt) 2011-11-08
KR101157004B1 (ko) 2012-07-09
AU2006323700B2 (en) 2011-02-17
TWI332838B (en) 2010-11-11
CA2630468A1 (en) 2007-06-14
PL1957073T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
CY1115171T1 (el) Ιατρικο φαρμακο
CY1119882T1 (el) Παραγωγο πυριμιδινης ως αναστολεας ρι3κ και χρηση αυτου
MX2024001824A (es) Compuestos heterociclicos y metodos de uso.
GB0005357D0 (en) Compounds
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
CY1111069T1 (el) Παραγωγα διυδροπυραζολοπυριμιδινονης
IL150481A0 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
CY1115548T1 (el) Ενωση κυκλικης αμινης και παραγων ελεγχου παρασιτων
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
WO2004018475A3 (en) Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
EA200701780A1 (ru) Противоопухолевое средство
JP2007514639A5 (el)
MY137964A (en) Benzofuran derivative
EA200971003A1 (ru) Бициклическое соединение и его фармацевтическое применение
ZA200703275B (en) 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury
ATE483689T1 (de) Pyrazolderivate als modulatoren von proteinkinase
MX387656B (es) Compuesto de pirrolo[2,3-d]pirimidina o sal del mismo.
MY144464A (en) Pyrazole derivatives as protien kinase modulators
EP4552638A3 (de) Tofa-analoga, zubereitungen zur sebumreduktion mit einem gehalt an solchen analoga und die kosmetische und/oder therapeutische verwendung solcher analoga als wirksames prinzip zur sebumreduktion oder -verhinderung
ATE461702T1 (de) Krebsmittel